Tevogen Bio Holdings (FRA:G28) Debt-to-Equity : -0.48 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings Debt-to-Equity?

Tevogen Bio Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €2.63 Mil. Tevogen Bio Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.04 Mil. Tevogen Bio Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €-5.58 Mil. Tevogen Bio Holdings's debt to equity for the quarter that ended in Sep. 2024 was -0.48.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Tevogen Bio Holdings's Debt-to-Equity or its related term are showing as below:

FRA:G28' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.35 Med: -1.05 Max: 0.12
Current: -0.26

During the past 3 years, the highest Debt-to-Equity Ratio of Tevogen Bio Holdings was 0.12. The lowest was -2.35. And the median was -1.05.

FRA:G28's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs FRA:G28: -0.26

Tevogen Bio Holdings Debt-to-Equity Historical Data

The historical data trend for Tevogen Bio Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings Debt-to-Equity Chart

Tevogen Bio Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

-1.42

0.12

-2.35

Tevogen Bio Holdings Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial					N/A	-2.35	-0.36	-0.26	-0.48

Competitive Comparison of Tevogen Bio Holdings's Debt-to-Equity

For the Biotechnology subindustry, Tevogen Bio Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tevogen Bio Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tevogen Bio Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Tevogen Bio Holdings's Debt-to-Equity falls into.

Tevogen Bio Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Tevogen Bio Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.497	+	0)	/	-0.638
	=	-2.35

Tevogen Bio Holdings's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.633	+	0.039)	/	-5.577
	=	-0.48

Tevogen Bio Holdings (FRA:G28) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Tevogen Bio Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Tevogen Bio Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tevogen Bio Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (FRA:G28) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

TVGN:USA G28:Germany

Address

15 Independence Boulevard, Warren, NJ, USA, 07059

Website

https://www.tevogen.com

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Headlines

No Headlines